
en e			
	one de la Particione de la Companya de la Companya Companya de la Companya de la Compa		San
Dockets lanagement Bran	nch	Di	ate: 5/5/0/
The Food and Drug Admir	nistration		
Depirtment of Health &H	uman Services, Rm. 1-23		
1240 Parklawn Dr.	•		
Rockville, MD 20857			
Re: 99P-1340/CP 1 — Petit	ion to Have Eternity eau de po	arfum declared "Misbranded"	
Dear Sir or Madam:		4384 "OI MAY 16 P	N 9-38
	nmental Health Network (EHN	I) submitted the above notiti	on to have Calvin Vlain's
	clared "misbranded." I am w		
	al attention with regard to your		
	tion 21CFR Sec. 740.10 states:	regulations = 2 Cr 10 Sec. 1 20	11, 210, 21, gee. 7, 10.2, and
	in a cosmetic product and each	ch finished cosmetic product	shall be adequately sub-
stantiated for safety prior to marketing. Any such ingredient or product whose safety is not adequately			
substantiated prior to marketing is misbranded unless it contains the following conspicuous statement on			
the principal display			• 4
	arning — The safety of this pr	W. MONT X. 3	
-	ernity contains toxic ingredier	its and ingredients whose saf	fety have not been substan-
iated. There is no warning label on its packaging.			
We all have a right to know the tatus of safety testing of the ingredients in products such as Eternity'so that			
we can protect ourselves and our families from toxic chemicals that may cause health problems. Most people			
are not aware that most fragrance materials have only limited safety testing. They wrongfully assume these			
products are safe buse in any setting and are surprised when people complain.			
Like tobacco sroke, the harmful chemicals currently used in these products may affect the health of many			
people, including people with asthma, chemical sensitivities, chronic fatigue, and other environmental illness-			
de .	ly vulnerable to toxic chemic		<u>•</u>
	chers. When I am exposed to the chemical fragrance produ		perience any of the follow-
			7
J anaphylaxis/shock		1 incoherence	nausea
anxiety, restlessness	□ ear pain	&incontinence	nose bleeds
asthma	CI eczema	irritability	□ rashes
J breathing difficulty	eyes, watery or dry	joint aches	seizures
□ bronchitis -	a fatigue	laryngitis	D short-term mem. loss
can't concentrate	flushing	lehargy lymph nodes swell	sinusitis
coughing	☐ headaches	• • •	sneezing
J depression	☐ heart beat irregularity	mood swings	sores, skin/mouth
disorientation	☐ hives	muscle pain/weakness	Swallowing difficulty Finnitus
D dizziness Dother:	□ hypertension	☐ nasal congestion	ip uninus
•			
	e millions of people who hav	- ·	, ,
=	, at school and in social settin	=	4
=	and chemical sensitivities. To	oxic chemicals in fragrances	have already ruined
countless lives. Thank you	•		
Sincerely,		2 1/1	
Zone Ball	MyD-KATEN	BAHNNOR	
our name			
Low Ballaryo - KATEN BAHLAROP our name Cannon/eague De., Austin, Th. 38745			
aaress; aty/st/zip			
Marialathana and accommi	والمنتقم والمناز والمراج والمتعددا والمناز والمراز والمراز	Joann annie alema Authoreus (1971 de a	and TATOLTTO ALL DTO A Landon-1

Newsletters and everyone who feels people have a right to know, please copy, share, tell your friends and WRITE the FDA... today!

HFA 305





Attn: 99P-1340/CP 1

Dockets Management Branch
The Food and Drug Administration
Department of He&h &Human Services, Rm. 1-23
12420 Parkla wn Dr.
Rockville, MD 20857

haldhadalahdaallahl

second, fold up